HALO: Subcutaneous delivery platforms drive record growth, new deals, and expanding royalty streams
Record revenue growth is driven by expanding subcutaneous drug delivery platforms, with multiple new deals and launches across ENHANZE and HyperCon. The company is diversifying royalty streams, investing in manufacturing scale-up, and maintaining strong capital allocation discipline.Based on Halozy…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.